It is even possible that the insulin-stimulating, glucagon-suppressing effects of the peptide or a more active synthetic analogue may be useful in the treatment of non-insulin-dependent diabetes, in which both impaired insulin release in response to glucose and persistent hyperglucagonemia are thought to be key pathophysiological abnormalities' (Kreymann, Ghattei, Williams, Bloom)
Starting at the lowest dose and increasing the dose gradually over time may help to minimize side effects
That year two different groups published papers indicating that secretin could lower blood glucose
Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes
The two scientists overcame the problem by engineering fatty acids that bound more strongly to albumin so that it would stick longer to GLP which would make it remain active for longer in the body
Possibly, but usually mild